<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-ONC-17013648</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-12-02</date_registration>
      <primary_sponsor>Beijing Boren Hospita</primary_sponsor>
      <public_title>Phase I study of sequential chimeric antigen receptor T cells targeting at different B-cell antigens in relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation</public_title>
      <acronym />
      <scientific_title>Phase I study of sequential chimeric antigen receptor T cells targeting at different B-cell antigens in relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2017-12-04</date_enrolment>
      <type_enrolment />
      <target_size>Case series:20;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=23337</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>Relapsed B acute lymphoblastic leukemia  after allo-HCT</hc_freetext>
      <i_freetext>Case series:sequential chimeric antigen receptor T cells treatment;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Biping Deng</firstname>
        <middlename />
        <lastname />
        <address> 6 Zhengwangfen South, Fengtai District, Beijing, China </address>
        <city />
        <country1 />
        <zip>100070</zip>
        <telephone>+86 18600940225</telephone>
        <email>dengbp@borenhospital.com</email>
        <affiliation>Beijing Boren Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Chunrong Tong</firstname>
        <middlename />
        <lastname />
        <address>6 Zhengwangfen South, Fengtai District, Beijing, China </address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13601301042/010-63290606 </telephone>
        <email>tongcr@borenhospital.com</email>
        <affiliation>Beijing Boren Hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Relapsed or refractory patients who have been diagnosed as CD19+/CD22+/CD20+  B-cell acute lymphoblastic leukemia (&gt; 99% of leukemia cells express CD19/CD22/CD20),and all of these patients relapsed after allogeneic hematopoietic stem cell transplantation(In line with NCCN,2015.2);
2. Aged 1 to 70 years; 
3. Patients with self-awareness and older than 18 years, who have the ability to sign the consent form and voluntary consent; 
4. Pediatric patients' legal guardians or the clients authorized by patients sign the consent form and are voluntary to participate in the clinical trials.  </inclusion_criteria>
      <agemin>1</agemin>
      <agemax>70</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Intracranial hypertension or unconsciousness; 
2. Symptomatic heart failure or severe cardiac arrhythmia; 
3. Respiratory failure; 
4. With other types of malignant tumors; 
5. Disseminated intravascular coagulation; 
6. Serum creatinine and/or urea nitrogen≥1.5 ×normal; 
7. Sepsis or other uncontrolled active infection; 
8. Uncontrolled diabetes; 
9. Severe mental disorder; 
10. Obvious intracranial lesions examined by head MRI; 
11. Cerebrospinal fluid leukemia cells&gt; 20/ul; 
12. Ratio of blood leukemia cell &gt; 30%; 
13. WHO physical status classification level≥3; 
14. Organ transplant recipients; 
15. Pregnant or lactating women;
16. With ≥3 aGVHD  or activity and widely cGVHD.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>safety;Ratio of bone marrow and peripheral B leukemia cells;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Beijing Boren Hospital </source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-11-16</approval_date>
        <contact_name>Tong Wu</contact_name>
        <contact_address>6 Zhengwangfen South, Fengtai district, Beijing, China  </contact_address>
        <contact_phone>+86 13801044860</contact_phone>
        <contact_email>wut@borenhospital.com </contact_email>
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>